Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026884 · ClinicalTrials.gov registry record
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
A clinical trial of Bladder Cancer and Kidney Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 5,950
- Enrollment target
- 1
- Study location
NCT00026884: Recruiting study of Bladder Cancer and Kidney Cancer, sponsored by National Cancer Institute (NCI).
NCT00026884 is a study of Bladder Cancer and Kidney Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 5,950 participants, below the 12,720-participant average among 175 other Bladder Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026884, a study of Bladder Cancer and Kidney Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 5,950 participants
- Enrollment target
- 1
- Study location
Study Summary
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....
Primary Outcome
Prostate cancer participants that have improvement in quality of life
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,950 participants |
| Start Date | 1998-03-12 |
What NCT00026884 shows while recruiting
NCT00026884 is an observational study that tracks outcomes without assigning an intervention. Its 5,950 participants enrollment target places it among the larger protocols in the corpus, below the 12,720-participant average among 175 other Bladder Cancer trials with a reported enrollment target (53% lower).
The record links to 5 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00026884 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00026884 about?
NCT00026884 is a clinical study titled "Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease". Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the ...
What is the current status of trial NCT00026884?
This trial is currently recruiting. The enrollment target is 5,950 participants. The study started on 1998-03-12.
What conditions does trial NCT00026884 study?
This clinical trial studies the following conditions: Bladder Cancer, Kidney Cancer, Renal Cancer, Malignant Neoplasms, Hereditary Neoplastic Syndromes.
Who is sponsoring clinical trial NCT00026884?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026884 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00026884's enrollment target sits among peer trials
5,950 6th of 175 higher than 170 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI